Phaseline

Companies › River 2 Renal

River 2 Renal: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Genitourinary; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
R2R01
Relaxin receptor agonist
RXFP1Phase 2Acute Kidney InjuryApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07625553R2R01Phase 2Acute Kidney InjuryGenitourinaryApr 2027

Targets

RXFP1 (1)

Companies with the same targets

–

Companies built like this

Tioga Pharmaceuticals Azure Biotech Gesynta Pharma Suzhou Sanegene Bio R1 Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.